Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

24 Feb 2020

• By Joseph Haas

Graphic Move On Forward Icon Concept — NGM's aldafermin shows strong data in Phase II, moves closer to pivotal study

Related Content

Stealthy NGM And Bristol Emerge As Serious NASH Competitors

25 Apr 2017

NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs

05 Dec 2018

NASH Companies Take The Stage At AASLD

15 Nov 2019

89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

11 Feb 2020

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

05 Apr 2019

Intercept’s Early NASH Efforts Will Stress Advanced Fibrosis

17 Dec 2019

Related Companies

NGM Biopharmaceuticals, Inc.

Bristol Myers Squibb Company

89bio, Inc.

Merck & Co., Inc.

Additional Topics

Clinical Trials Business Strategies Drug Approval Standards Research & Development Liver & Hepatic Metabolic Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.